SNIPR BIOME and Novo Nordisk have entered into a research agreement on an undisclosed target to evaluate SNIPR BIOME's proprietary technology for in situ production of therapeutics in the human microbiome

SNIPR Biome's unique delivery technology spans both CRISPR-based phage delivery and bacterial conjugation delivery and can be used for both precision killing of bacteria or engineering any therapeutic protein or peptide to be expressed in the gut microbiota.

"We look forward to working with Novo Nordisk and further validating our CRISPR-based CGV Vector™ technology", says CEO and Co-founder Christian Grøndahl. He continues: *"Our unique and patented technology has many different applications. Delivering genes to the microbiome to enable in situ production of proteins and peptides has almost unlimited potential. Engineered proteins and peptides can be enzymes that target unwanted gut metabolites, anti-cytokines to dampen autoimmune inflammation in e.g. IBD, immune-oncology antibodies, or signalling molecules/hormones. The potential scope for our technology is extensive."*

Read more about SNIPR BIOME and our technology here.

SNIPRBIOME
A CRISPR COMPANY